AB5078P
Anti-Beta-Amyloid 1-42 Antibody
Chemicon®, from rabbit
Synonym(s):
Anti-AAA, Anti-ABETA, Anti-ABPP, Anti-AD1, Anti-APPI, Anti-CTFgamma, Anti-CVAP, Anti-PN-II, Anti-PN2, Anti-alpha-sAPP, Anti-preA4
Sign Into View Organizational & Contract Pricing
All Photos(3)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
rabbit
Quality Level
antibody form
affinity purified immunoglobulin
antibody product type
primary antibodies
clone
polyclonal
purified by
affinity chromatography
species reactivity
chicken, mouse, human
manufacturer/tradename
Chemicon®
technique(s)
ELISA: suitable
immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... APP(351)
General description
The cerebral and vascular plaques associated with Alzheimer′s disease (AD) are mainly composed of amyloid beta peptides (Ab). Ab is derived from cleavage of the amyloid precursor protein (APP) and varies in length from 39 to 43 amino acids. Ab [1-40], Ab [1-42], and Ab [1-43] peptides result from cleavage of APP after residues 40, 42, and 43, respectively. The cleavage takes place by gamma-secretase during the last APP processing step. Ab [1-40], [1-42] and [1-43] peptides are major constituents of the plaques and tangles that occur in AD. Ab antibodies and peptides have been developed as tools for elucidating the biology of AD.
Specificity
Recognizes beta-amyloid 1-42. Antibody does not show appreciable reactivity with beta amyloid 1-40 as detected by ELISA.
One of the most important and initial steps which causes loss of memory and cognition in Alzheimer’s Disease (AD) involves proteolytic cleavage of amyloid precursor protein (APP, chromosome 21) releasing short 40, 42 & 43 amino acid peptides (beta amyloid 1-40, 1-42 and 1-43). Polymerization of beta-amyloid and subsequent neuronal deposit (amyloid) leads to the degeneration of neurons involved in memory and cognition.
One of the most important and initial steps which causes loss of memory and cognition in Alzheimer’s Disease (AD) involves proteolytic cleavage of amyloid precursor protein (APP, chromosome 21) releasing short 40, 42 & 43 amino acid peptides (beta amyloid 1-40, 1-42 and 1-43). Polymerization of beta-amyloid and subsequent neuronal deposit (amyloid) leads to the degeneration of neurons involved in memory and cognition.
Immunogen
A six amino acid peptide sequence from the C-terminal of human beta-amyloid 1-42.
Epitope: C-terminus
Application
Anti-Beta-Amyloid 1-42 Antibody is an antibody against Beta-Amyloid 1-42 for use in ELISA, IH, IH(P) & WB.
Immunohistochemistry (Paraffin) Analysis:
Western Blot:
1-10 µg/mL of a previous lot was used. (Chemiluminescence technique).
ELISA:
1:10,000-1:100,000 of a previous lot was used using 50-100 ng immunogen peptide/well.
Optimal working dilutions must be determined by the end user.
Western Blot:
1-10 µg/mL of a previous lot was used. (Chemiluminescence technique).
ELISA:
1:10,000-1:100,000 of a previous lot was used using 50-100 ng immunogen peptide/well.
Optimal working dilutions must be determined by the end user.
Research Category
Neuroscience
Neuroscience
Research Sub Category
Neurodegenerative Diseases
Neurodegenerative Diseases
Quality
Routinely evaluated by immunohistochemistry (paraffin) on Alzheimer’s Disease-Brain.
Immunohistochemistry (Paraffin) Analysis:
Beta-Amyloid (cat. # AB5078P) staining on Alzheimer’s Disease-Brain. Tissue pretreated with Citrate, pH 6.0. The antibody was diluted to 1:35, using IHC-Select Detection with HRP-DAB. Immunoreactivity is seen as staining on plaque deposits (brown) or as cerebral vascular amyloid deposition in the walls of blood vessels (brown).
Immunohistochemistry (Paraffin) Analysis:
Beta-Amyloid (cat. # AB5078P) staining on Alzheimer’s Disease-Brain. Tissue pretreated with Citrate, pH 6.0. The antibody was diluted to 1:35, using IHC-Select Detection with HRP-DAB. Immunoreactivity is seen as staining on plaque deposits (brown) or as cerebral vascular amyloid deposition in the walls of blood vessels (brown).
Physical form
ImmunoAffinity Purified
Purified rabbit polyclonal in liquid buffer containing PBS with 0.1% BSA.
Storage and Stability
Stable for 1 year at -20ºC from date of receipt.
Analysis Note
Control
Alzheimer′s disease brain tissue, whole tissue extracts from mouse brain. C03-801.
Alzheimer′s disease brain tissue, whole tissue extracts from mouse brain. C03-801.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class
12 - Non Combustible Liquids
wgk_germany
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Accumulation of intraneuronal ?-amyloid 42 peptides is associated with early changes in microtubule-associated protein 2 in neurites and synapses.
Takahashi, RH; Capetillo-Zarate, E; Lin, MT; Milner, TA; Gouras, GK
Testing null
Chronic thrombin exposure results in an increase in apolipoprotein-E levels.
Mhatre, M; Hensley, K; Nguyen, A; Grammas, P
Journal of Neuroscience Research null
Ramon Velazquez et al.
Molecular neurodegeneration, 11(1), 52-52 (2016-07-15)
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder worldwide. Clinically, AD is characterized by impairments of memory and cognitive functions. Accumulation of amyloid-β (Aβ) and neurofibrillary tangles are the prominent neuropathologies in patients with AD. Strong evidence indicates that
Constantinos D Paspalas et al.
Alzheimer's & dementia : the journal of the Alzheimer's Association, 14(5), 680-691 (2017-12-16)
An animal model of late-onset Alzheimer's disease is needed to research what causes degeneration in the absence of dominant genetic insults and why the association cortex is particularly vulnerable to degeneration. We studied the progression of tau and amyloid cortical
Matthew M Harper et al.
Investigative ophthalmology & visual science, 60(7), 2716-2725 (2019-06-28)
Traumatic brain injury (TBI) is a risk factor for developing chronic neurodegenerative conditions including Alzheimer's disease (AD). The purpose of this study was to examine chronic effects of blast TBI on retinal ganglion cells (RGC), optic nerve, and brain amyloid
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service